Literature DB >> 25457431

The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data.

Mark E Schmidt1, Ping Chiao2, Gregory Klein3, Dawn Matthews4, Lennart Thurfjell5, Patricia E Cole6, Richard Margolin7, Susan Landau8, Norman L Foster9, N Scott Mason10, Susan De Santi11, Joyce Suhy3, Robert A Koeppe12, William Jagust8.   

Abstract

In vivo imaging of amyloid burden with positron emission tomography (PET) provides a means for studying the pathophysiology of Alzheimer's and related diseases. Measurement of subtle changes in amyloid burden requires quantitative analysis of image data. Reliable quantitative analysis of amyloid PET scans acquired at multiple sites and over time requires rigorous standardization of acquisition protocols, subject management, tracer administration, image quality control, and image processing and analysis methods. We review critical points in the acquisition and analysis of amyloid PET, identify ways in which technical factors can contribute to measurement variability, and suggest methods for mitigating these sources of noise. Improved quantitative accuracy could reduce the sample size necessary to detect intervention effects when amyloid PET is used as a treatment end point and allow more reliable interpretation of change in amyloid burden and its relationship to clinical course.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ADNI; Alzheimer's disease; Amyloid; Multi-site trials; Positron emission tomography; Quantitative analysis; Within subject variability

Mesh:

Substances:

Year:  2014        PMID: 25457431     DOI: 10.1016/j.jalz.2014.09.004

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  44 in total

1.  A Fully Automatic Technique for Precise Localization and Quantification of Amyloid-β PET Scans.

Authors:  Mouna Tahmi; Wassim Bou-Zeid; Qolamreza R Razlighi
Journal:  J Nucl Med       Date:  2019-06-06       Impact factor: 10.057

Review 2.  Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2017-03-22       Impact factor: 21.566

3.  Optimizing PiB-PET SUVR change-over-time measurement by a large-scale analysis of longitudinal reliability, plausibility, separability, and correlation with MMSE.

Authors:  Christopher G Schwarz; Matthew L Senjem; Jeffrey L Gunter; Nirubol Tosakulwong; Stephen D Weigand; Bradley J Kemp; Anthony J Spychalla; Prashanthi Vemuri; Ronald C Petersen; Val J Lowe; Clifford R Jack
Journal:  Neuroimage       Date:  2016-08-27       Impact factor: 6.556

4.  Longitudinal Positron Emission Tomography in Preventive Alzheimer's Disease Drug Trials, Critical Barriers from Imaging Science Perspective.

Authors:  Sepideh Shokouhi; Desmond Campbell; Aaron B Brill; Harry E Gwirtsman
Journal:  Brain Pathol       Date:  2016-09       Impact factor: 6.508

5.  Validation of a spatial normalization method using a principal component derived adaptive template for [18F]florbetaben PET.

Authors:  Antoine Leuzy; Kerstin Heurling; Susan De Santi; Santiago Bullich; Oskar Hansson; Johan Lilja
Journal:  Am J Nucl Med Mol Imaging       Date:  2020-08-25

6.  White Matter Reference Region in PET Studies of 11C-Pittsburgh Compound B Uptake: Effects of Age and Amyloid-β Deposition.

Authors:  Val J Lowe; Emily S Lundt; Matthew L Senjem; Christopher G Schwarz; Hoon-Ki Min; Scott A Przybelski; Kejal Kantarci; David Knopman; Ronald C Petersen; Clifford R Jack
Journal:  J Nucl Med       Date:  2018-04-19       Impact factor: 10.057

7.  Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials.

Authors:  Enchi Liu; Mark E Schmidt; Richard Margolin; Reisa Sperling; Robert Koeppe; Neale S Mason; William E Klunk; Chester A Mathis; Stephen Salloway; Nick C Fox; Derek L Hill; Andrea S Les; Peter Collins; Keith M Gregg; Jianing Di; Yuan Lu; I Cristina Tudor; Bradley T Wyman; Kevin Booth; Stephanie Broome; Eric Yuen; Michael Grundman; H Robert Brashear
Journal:  Neurology       Date:  2015-07-24       Impact factor: 9.910

Review 8.  The impact of the Alzheimer's Disease Neuroimaging Initiative 2: What role do public-private partnerships have in pushing the boundaries of clinical and basic science research on Alzheimer's disease?

Authors:  Dorothy M Jones-Davis; Neil Buckholtz
Journal:  Alzheimers Dement       Date:  2015-07       Impact factor: 21.566

9.  GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP.

Authors:  Vijay K Ramanan; Shannon L Risacher; Kwangsik Nho; Sungeun Kim; Li Shen; Brenna C McDonald; Karmen K Yoder; Gary D Hutchins; John D West; Eileen F Tallman; Sujuan Gao; Tatiana M Foroud; Martin R Farlow; Philip L De Jager; David A Bennett; Paul S Aisen; Ronald C Petersen; Clifford R Jack; Arthur W Toga; Robert C Green; William J Jagust; Michael W Weiner; Andrew J Saykin
Journal:  Brain       Date:  2015-08-11       Impact factor: 13.501

10.  11C-Pittsburgh compound B and 18F-THK 5351 positron emission tomography brain imaging in cognitively normal individuals.

Authors:  Chanisa Chotipanich; Attapon Jantarato; Anchisa Kunawudhi; Supaporn Kongthai; Chetsadaporn Promteangtrong
Journal:  World J Nucl Med       Date:  2020-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.